{"id":"oros-oxybutynin","safety":{"commonSideEffects":[{"rate":"29-72","effect":"Dry mouth"},{"rate":"7-15","effect":"Constipation"},{"rate":"6-17","effect":"Dizziness"},{"rate":"1-8","effect":"Somnolence"},{"rate":"7-10","effect":"Headache"},{"rate":"1-8","effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxybutynin works by antagonizing acetylcholine at muscarinic receptors on detrusor muscle in the bladder, thereby decreasing the frequency and amplitude of bladder contractions. The OROS (osmotic release oral system) formulation provides extended-release delivery, allowing once-daily dosing with improved tolerability compared to immediate-release formulations by reducing peak plasma concentrations.","oneSentence":"OROS oxybutynin is an anticholinergic agent that blocks muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:49.153Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"},{"name":"Neurogenic detrusor overactivity in spinal cord injury patients"}]},"trialDetails":[{"nctId":"NCT00269750","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1996-07","conditions":"Urge Incontinence","enrollment":100},{"nctId":"NCT00304499","phase":"PHASE3","title":"Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1995-12","conditions":"Urinary Incontinence","enrollment":176},{"nctId":"NCT00269724","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1997-03","conditions":"Urinary Incontinence","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OROS® oxybutynin","genericName":"OROS® oxybutynin","companyName":"Alza Corporation, DE, USA","companyId":"alza-corporation-de-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OROS oxybutynin is an anticholinergic agent that blocks muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in spinal cord injury patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}